Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07007078

Efficacy of Dihydroartemisinin for Treating Acne Vulgaris

The goal of this clinical trial is to learn if dihydroartemisinin (DHA) works to treat Acne Vulgaris in adults. The main question it aims to answer is:

• Does DHA improve the acne severity by at least one grade after treatment. Researchers will treat patients who are clinically diagnosed as Acne Vulgaris to see if DHA works to alleviate the symptoms of Acne Vulgaris.

Participants will:

* Take DHA every day for 3 months * Visit the clinic once every month for checkups and tests

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Acne Vulgaris Acneiform Eruptions Sebaceous Gland Diseases Skin Diseases Skin and Connective Tissue Diseases

Age range

18 year–40 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

Zhongshan Hospital Fudan University

Shanghai, Shanghai Municipality, 200032, China

Location status: Recruiting

Location contact

Lujuan GAO, MD, PhD

CONTACT

[email protected]

86-021-64041990

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically diagnosed with acne vulgaris;
  • For female patients, no pregnancy plans within the next 6 months.

Exclusion criteria

  • Patients who have used sex hormones or other systemic medications for acne treatment within the past 3 months;
  • Patients who have used topical medications for acne within the past 2 weeks;
  • Pregnant or breastfeeding women;
  • Patients with known severe diseases of vital organs (e.g., heart, liver, kidney) or malignancies.

Treatment and study plan

Dihydroartemisinin

Drug

DHA 40mg tid for 90 days

Primary outcomes

  1. Improvement of acne severity by Investigator's Global Assessment (IGA)

    Time frame: Before and immediately after 90-day treatment

    Improvement of acne severity is considered clinically significant if a subject's IGA improves by at least one grade

Secondary outcomes

  1. Change of Global Acne Grading System (GAGS) score from baseline to the end of treatment

    Time frame: Before and immediately after 90-day treatment

    An improvement of ≥30% in the GAGS score will be considered significant

  2. Change of inflammatory lesion count from baseline to the end of treatment

    Time frame: Before and immediately after 90-day treatment

  3. Change of non-inflammatory lesion count from baseline to the end of treatment

    Time frame: Before and immediately after 90-day treatment

  4. Number of participants who achieved an IGA score of 0 or 1 at the end of treatment

    Time frame: Before and immediately after 90-day treatment

  5. Change of serum total testosterone from baseline to the end of treatment

    Time frame: Before and immediately after 90-day treatment

Study contacts

Contact information is provided by the study sponsor or research team.

Lujuan GAO, MD, PhD

CONTACT

[email protected]

86-021-64041990

Sponsors and collaborators

Lead sponsor

Shanghai Zhongshan Hospital

Other

Registry information

Official study title

A Pilot Study to Evaluate the Therapeutic Effect of Dihydroartemisinin on Acne Vulgaris

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jun 5, 2025
Registry last updated
Jun 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.